Literature DB >> 17912546

The Wilms' tumor suppressor WT1 is associated with melanoma proliferation.

Nicole Wagner1, John Panelos, Daniela Massi, Kay-Dietrich Wagner.   

Abstract

Expression of the Wilms' tumor suppressor WT1 has been demonstrated in a variety of tumors and tumor cell lines, e.g., in breast cancer and melanoma cell lines. Its role is controversial, with evidence for both tumor-promoting and tumor-suppressing activities. In this paper, we show that WT1 is expressed in malignant melanoma in >80% of the tumor cells, but not in normal skin or benign melanocytic nevi in vivo. We detected an unusual shift of WT1 isoforms towards WT1(+17AA/+KTS) in melanoma. WT1 shared an overlapping expression with proliferating nuclear cell antigen and with Nestin and Zyxin, which are involved in melanoma cell proliferation. To investigate whether WT1 is directly involved in melanoma cell proliferation, we made use of an RNAi approach in vitro. WT1 silencing significantly reduced the expression of Nestin and Zyxin and resulted in inhibition of melanoma cell proliferation as determined by a reduced BrdU incorporation. These findings suggest a direct role of WT1 in melanoma proliferation, which might be mediated via Nestin and Zyxin. Furthermore, expression of WT1 in vivo clearly discriminates between benign acquired nevi and malignant melanomas and appears to be correlated with melanocytic atypia and malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912546     DOI: 10.1007/s00424-007-0340-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  32 in total

1.  Increased expression of stem cell markers in malignant melanoma.

Authors:  Walter M Klein; Bryan P Wu; Shuping Zhao; Hong Wu; Andres J P Klein-Szanto; Steven R Tahan
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

2.  Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.

Authors:  M R Foster; J E Johnson; S J Olson; D C Allred
Journal:  Arch Pathol Lab Med       Date:  2001-10       Impact factor: 5.534

3.  HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.

Authors:  Musaffe Tuna; Arturo Chavez-Reyes; Ana M Tari
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

4.  Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells.

Authors:  E A Burwell; G P McCarty; L A Simpson; K A Thompson; D M Loeb
Journal:  Oncogene       Date:  2006-12-11       Impact factor: 9.867

5.  The Wilms' tumor suppressor Wt1 is associated with the differentiation of retinoblastoma cells.

Authors:  Nicole Wagner; Kay-Dietrich Wagner; Gunnar Schley; Sarah E Coupland; Heinrich Heimann; Rosemarie Grantyn; Holger Scholz
Journal:  Cell Growth Differ       Date:  2002-07

6.  Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors.

Authors:  Marick E Lae; Patrick C Roche; Long Jin; Ricardo V Lloyd; Antonio G Nascimento
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

7.  WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.

Authors:  M Al-Hussaini; A Stockman; H Foster; W G McCluggage
Journal:  Histopathology       Date:  2004-02       Impact factor: 5.087

8.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.

Authors:  Yusuke Oji; Shinichiro Miyoshi; Hajime Maeda; Seiji Hayashi; Hiroya Tamaki; Shin-Ichi Nakatsuka; Masayuki Yao; Eigo Takahashi; Yoko Nakano; Hirohisa Hirabayashi; Yasushi Shintani; Yoshihiro Oka; Akihiro Tsuboi; Naoki Hosen; Momotaro Asada; Tatsuya Fujioka; Masaki Murakami; Keisuke Kanato; Mari Motomura; Eui Ho Kim; Manabu Kawakami; Kazuhiro Ikegame; Hiroyasu Ogawa; Katsuyuki Aozasa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Cancer       Date:  2002-07-20       Impact factor: 7.396

Review 9.  The many facets of the Wilms' tumour gene, WT1.

Authors:  Peter Hohenstein; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

10.  Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds.

Authors:  N G Burnet; S J Jefferies; R J Benson; D P Hunt; F P Treasure
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  17 in total

1.  Downregulation of the WT1 gene expression via TMPyP4 stabilization of promoter G-quadruplexes in leukemia cells.

Authors:  Saeedeh Ghazaey Zidanloo; Abasalt Hosseinzadeh Colagar; Hossein Ayatollahi; Jahan-Bakhsh Raoof
Journal:  Tumour Biol       Date:  2016-01-27

Review 2.  Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation.

Authors:  Holger Scholz; Kay-Dietrich Wagner; Nicole Wagner
Journal:  Pflugers Arch       Date:  2008-12-04       Impact factor: 3.657

3.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

4.  WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

Authors:  Santiago Saavedra-Alonso; Pablo Zapata-Benavides; Ana Karina Chavez-Escamilla; Edgar Manilla-Muñoz; Diana Elisa Zamora-Avila; Moisés Armides Franco-Molina; Cristina Rodriguez-Padilla
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

Review 5.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

6.  WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi.

Authors:  Karli Rosner; Darius R Mehregan; Darius Moussai; Judith Abrams; Gerard Tromp; David A Mehregan
Journal:  J Cutan Pathol       Date:  2009-07-09       Impact factor: 1.587

7.  A novel Wilms' tumor 1 gene mutation in a child with severe renal dysfunction and persistent renal blastema.

Authors:  Nicole Wagner; Kay-Dietrich Wagner; Mickael Afanetti; Fabien Nevo; Corinne Antignac; Jean-Francois Michiels; Andreas Schedl; Etienne Berard
Journal:  Pediatr Nephrol       Date:  2008-05-31       Impact factor: 3.714

8.  Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Authors:  Daphné Benteyn; Sébastien Anguille; Sandra Van Lint; Carlo Heirman; An Mt Van Nuffel; Jurgen Corthals; Sebastian Ochsenreither; Wim Waelput; Katrien Van Beneden; Karine Breckpot; Viggo Van Tendeloo; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther Nucleic Acids       Date:  2013-11-19       Impact factor: 10.183

9.  PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.

Authors:  Jean-François Michiels; Christophe Perrin; Nathalie Leccia; Daniela Massi; Paul Grimaldi; Nicole Wagner
Journal:  Pflugers Arch       Date:  2010-01-12       Impact factor: 3.657

10.  A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems.

Authors:  Mariana H Massaoka; Alisson L Matsuo; Carlos R Figueiredo; Natalia Girola; Camyla F Faria; Ricardo A Azevedo; Luiz R Travassos
Journal:  FEBS Open Bio       Date:  2014-01-21       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.